Nervo (NYSE:NVRO) this week announced it appointed Kevin Thornal as CEO and president, effective April 24.

Thornal succeeds D. Keith Grossman, who is retiring, also effective April 24. Grossman will be appointed to serve as executive chair of the company.

“On behalf of the board and our entire company, I am excited to welcome Kevin to the Nevro team,” Grossman said in a news release. “Throughout his career, Kevin has established an excellent track record of leading medical technology businesses that deliver strong growth and commercial excellence. Kevin is an impressive rising leader in our industry and is an ideal fit in every way with where Nevro is today and where we believe it can go in the future. It’s been a great privilege to lead this company over the past four years and extremely rewarding to work alongside the talented and dedicated individuals who are committed to Nevro’s vision, mission and values. I look forward to a smooth transition and to working to support Kevin and his team as executive chairman.”

Thornal has more than 20 years of senior management experience, including nine years at Hologic where he most recently served as group president of global diagnostic solutions. He also was VP of customer experience, field service and clinical applications for Hologic’s breast and skeletal health division. Thornal has held numerous other leadership roles at Hologic and Stryker.

“I am delighted to join Nevro at this exciting time and look forward to furthering its mission of delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment,” said Thornal. “Keith and the Nevro team have built a powerful platform for Nevro’s future. I am proud to join this talented team and am committed to further advancing Nevro’s vision and strategy and to delivering attractive returns to our shareholders.”